Event Participants
Executives
2 Jitendra Sharma, Mark Saldanha
Analysts
10 Abhi Jain, Aejas Lakhani, Ahmed Madha, Amit, Anand Munot, Deepesh Sancheti, Jugal Shah, Mihir Damania, Nitin Agarwal, Vishal Manchanda
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Operating Revenue | ₹840.8 crores | Up 35.6% YoY from ₹620 crore; broad-based growth across all geographies |
| North America Revenue | ₹377 crores | Up 15.1% YoY; ~45% of consolidated revenue; summer seasonal softness expected to reverse |
| UK & Europe Revenue | ₹356 crores | Up 74.7% YoY; highest ever quarterly; includes ~₹44 cr from Clinique BV; ex-acquisition growth 53.1% YoY |
| ANZ Revenue | ₹88 crores | Up 53.7% YoY; sequential moderation in line with southern hemisphere winter seasonality post strong Q4 |
| Rest of World Revenue | ₹20 crores | War-related transportation disruptions; small base cushions impact |
| Gross Profit | ₹497.3 crores | Up 38.9% YoY; margin 59.1% (+138 bps YoY, +478 bps QoQ); favorable product mix, low-cost inventory, FX tailwinds |
| EBITDA | ₹213 crores | Up 112.8% YoY; highest ever; margin 25.3% (+919 bps YoY, +251 bps QoQ); operating leverage |
| PAT | ₹159.4 crores | Up 173.9% YoY; highest ever; margin 18.4% vs 9.3% YoY and 17.4% sequentially |
| Cash Balance | ₹1,058 crores | First time crossing ₹1,000 crore; net cash ₹1,031 crore; up from ₹711 cr YoY despite Clinique payment |
| Cash from Operations | ₹185 crores | Free cash flow ₹152 cr after net CapEx of ₹33 cr |
| Working Capital Cycle | ~132 days | Improved from ~159 days YoY and ~138 days sequentially |
| R&D Spend | ₹23.2 crores | 2.8% of revenue vs 2.0% YoY; focus on differentiated dosage forms |
Geographic & Segment Commentary
North America: Revenue of ₹377 crores, up 15.1% YoY, representing ~45% of consolidated revenue. Softer summer demand in line with normal seasonal patterns; Rx price erosion in single digits. Order book remains strong and management expects momentum to strengthen; US mix shifting from ~95/5 OTC/Rx toward 85/15.
UK & Europe: Revenue of ₹356 crores, up 74.7% YoY, the highest ever for the region and ~42% of consolidated revenue. Clinique BV (Netherlands) contributed ~₹44 crores; ex-acquisition organic growth 53.1% YoY. Clinique guided at ₹150-175 crores FY27; Europe total ~₹180 crores; Germany revenue expected from Q3, Ireland from next fiscal.
Australia & New Zealand: Revenue of ₹88 crores, up 53.7% YoY. Sequential moderation follows particularly strong Q4 (southern hemisphere winter season); underlying business healthy with momentum expected to build through the year.
Rest of World: Revenue of ₹20 crores during the quarter. Non-Western markets facing transportation hurdles (vessels unable to pass, rising freight) due to war scenarios; limited contribution minimizes impact on overall performance.
Company-Specific & Strategic Commentary
European Expansion: Completed Clinique BV (Netherlands) acquisition (effective April 1, 2026) and ABC Now GmbH (Germany) consolidation from Q2; established Marksans Pharma GmbH (Germany) and Marksans Pharma Limited Europe (Ireland). Targeting ~₹1,000 crore Europe revenue within 3-5 years, primarily through acquisitions.
Inorganic Growth Pipeline: Cash crossed ₹1,000 crore with net cash of ₹1,031 crore; management actively exploring larger deals in Europe and India, positioning FY27 as the year of inorganic strategy execution to evolve the company.
Manufacturing Expansion: Goa Unit 2 (Teva facility) generating ₹50+ crore revenue against ₹80 crore target (~60-65% progress). New manufacturing unit evaluation underway with a 1-2 year timeline; location flexible across states.
R&D & Product Portfolio: R&D spend increased to 2.8% of revenue (₹23.2 crore); objective to double product portfolio in every geography over the next 2-3 years; focus on differentiated dosage forms.
US Strategy: Next milestone $300 million revenue with potential $400 million in 5 years; Rx mix increasing from ~5% toward 15% while OTC remains core strength. Canada presence established with product filings underway. 65-70% of sales manufactured in India.
Consumer Healthcare Vision 2030: Strategic ambition to become a top global consumer healthcare company by 2030; focus on OTC brand creation and portfolio expansion with continued resource investment.
Capital Discipline: Management remains risk-averse on cash deployment, prioritizing inorganic strategies with fast returns (citing Netherlands deal) over yield-bearing instruments; working capital cycle improved to ~132 days.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| FY27 Revenue Growth | 15-20% | Maintained despite Q1 at 35.6% YoY; geopolitical volatility and war scenarios cited for holding guidance |
| FY27 EBITDA Margin | 20-21% | Management standing by plan; year-end 21-22% EBITDA achievable per commentary despite Q1 25.3% |
| Revenue Target | ₹4,000 crores within 2 years | On track; all geographies expected to contribute versus last year when UK underperformed |
| Long-term Revenue | Doubling current ~₹3,000 crore base in 5 years | Management reiterated doubling revenue visibility |
| Gross Margin | Normalize to 55-56% | From 59.1% Q1; low-cost inventory unwinding; war impacts on freight and raw material costs |
| Clinique FY27 Revenue | ₹150-175 crores | Consolidated from April 1, 2026; ~40% growth over historical €10 million baseline |
| Germany Revenue | Q3 FY27 start | ABC Now GmbH consolidation from Q2; meaningful revenue expected early third quarter |
| Ireland Revenue | FY28 (next fiscal) | Product, wholesale, and distribution licenses in process |
| Europe Revenue | ~₹180 crores FY27; ~₹1,000 crores in 3-5 years | Combination of acquisitions plus organic UK and continental Europe growth |
| US Revenue | $300 million next milestone; $400 million in 5 years | OTC-led with Rx gaining traction; Canada expansion underway with filings |
| Goa Unit 2 | ₹80 crore revenue target | Currently at ₹50+ crores (~60-65% of target) |
| Q2/Q3 Seasonality | Q2 revenue higher than Q1; Q3 strongest of FY27 | Normal seasonal pattern; revenue trajectory builds through the year |
Risks & Constraints
| Risk | Context |
|---|---|
| Geopolitical/War Disruption | Current war scenarios impacting freight costs, solvent/raw material pricing, and transportation to Rest of World markets. Management expects relatively fast normalization post-war, but timing uncertain; gross margin sustainability dependent on resolution. |
| Gross Margin Normalization | Record 59.1% gross margin partially driven by low-cost inventory unwinding. Management guided sustainable level of 55-56%; war-related cost inflation (crude, transportation) could pressure further. |
| US Tariff/Policy Risk | Potential 200% tariff on products mentioned under current administration; management dismisses near-term impact noting policy volatility and 2-year horizon; US manufacturing ramp-up kept as option. |
| US FDA Inspection | No definite timeline; inspections can occur anytime based on filings and ongoing activities; one plant audited less than 12 months ago. |
| Manufacturing Capacity Constraint | Potential run-out of manufacturing capacity for 3-5 year growth plan; new unit evaluation underway with 1-2 year timeline; valuation and pricing challenges noted. |
| M&A Integration & Execution Risk | Europe expansion depends on successful integration of Clinique BV and ABC Now GmbH; management acknowledges M&A unpredictability and variable timelines; additional acquisitions needed to reach ₹1,000 crore Europe target. |
Q&A Highlights
Clinique Acquisition & Europe Growth
- Question: How was Clinique revenue recognition handled given transaction timing, and what is the full-year outlook for acquisitions and organic Europe growth? (Ahmed Madha - Unifi Capital)
- Answer: Effective date April 1, 2026, so Q1 fully consolidated. Clinique expected at ~₹150-175 crore revenue for FY27; Europe total ~₹180 crore. Growth from Clinique expected at ~40% above historical €10 million baseline. (Jitendra Sharma, Mark Saldanha)
- Question: How sustainable is the 75% YoY UK/Europe growth? (Amit - Integrity Ventures)
- Answer: Management expects sustainability; Germany revenue starting early Q3, Netherlands already performing, Ireland from next fiscal year. (Mark Saldanha)
Gross Margin Sustainability
- Question: With record gross margins driven by low-cost inventory, how should we think about sustainability and pricing? (Ahmed Madha - Unifi Capital)
- Answer: Gross margin should settle at 55-56%; low-cost inventory being depleted; war impacts on freight and raw material costs are current headwinds; normalization expected relatively fast post-war. (Mark Saldanha)
- Question: Is there scope to push gross margins higher? (Vishal Manchanda - Systematix Group)
- Answer: 55-56% is the more comfortable range given war, crude, and transportation factors; pushing higher would be unrealistic. (Mark Saldanha)
FY27 Guidance & Seasonality
- Question: With Q1 at 25% EBITDA margin, will FY27 guidance of 15-20% revenue growth and 20-21% EBITDA margin be revised upward? (Amit - Integrity Ventures)
- Answer: No; sticking with plan due to geopolitical volatility. Year-end EBITDA of 21-22% achievable. (Mark Saldanha)
- Question: Q1 is typically a weak quarter - will Q2 and Q3 be stronger? (Deepesh Sancheti - Maanya Finance)
- Answer: Q2 revenue will be better than Q1, with Q3 likely the strongest quarter of the year. (Mark Saldanha)
European M&A Strategy
- Question: Are two European acquisitions enough, or will more be needed? (Deepesh Sancheti - Maanya Finance)
- Answer: More acquisitions will be needed; cash corpus available for inorganic strategies; valuation discipline maintained. (Mark Saldanha)
- Question: How do you see Europe shaping up over 3-5 years? (Anand Munot - OM Financial Advisory)
- Answer: Hoping for ~₹1,000 crore revenue from Europe within 5 years; most expansion via acquisitions/inorganic strategies. (Mark Saldanha)
US Strategy, Tariffs & Growth Outlook
- Question: What is the US strategy given potential 200% tariff after 2 years? Any plans to ramp US production? (Deepesh Sancheti - Maanya Finance)
- Answer: US ramp-up is always a possibility; not assigning weightage to presidential statements as policy may change; 2 years is a long horizon; political and election scenarios could shift landscape. (Mark Saldanha)
- Question: US outlook over next 3-5 years? (Nitin Agarwal - DAM Capital)
- Answer: Working toward $300 million as next benchmark, potentially $400 million in 5 years; OTC-driven but Rx gaining traction, shifting mix from 95/5 toward 85/15. (Mark Saldanha)
Capital Allocation & Cash Utilization
- Question: With ₹1,058 crore cash earning 4-5% post-tax against 20% operating ROC, will management consider better-yield products like index investing? (Abhi Jain - AJ Capital)
- Answer: No; risk-averse policy on cash deployment; priority is inorganic strategies with fast, lucrative returns such as the Netherlands deal; no speculative instruments. (Mark Saldanha)
- Question: Any larger acquisitions in the next 1-year horizon given the cash position? (Jugal Shah - Individual Investor)
- Answer: Anything possible; larger ticket deals in India would carry bigger valuations; 200-400 crore potential outflows; FY27 is the year of pursuing inorganic strategy to evolve the company. (Mark Saldanha)
Manufacturing & Capacity Expansion
- Question: Any incremental color on manufacturing capacity - greenfield or brownfield assets? (Aejas Lakhani - Unifi AMC)
- Answer: Looking at a couple of targets; 1-2 year timeline; another unit likely in India; location flexibility (open to other states); pricing discipline critical. (Mark Saldanha)
- Question: How is Goa Unit 2 progressing and what is the capacity? (Anand Munot - OM Financial Advisory)
- Answer: Currently generating ₹50+ crore revenue versus ₹80 crore projected target, representing ~60-65% progress. (Mark Saldanha)
R&D & Product Portfolio
- Question: How have R&D efforts progressed and what are the major objectives? (Nitin Agarwal - DAM Capital)
- Answer: Focus on differentiated dosage forms and product development; objective to double product portfolio in every geography over 2-3 years; R&D costs increasing with scale. (Mark Saldanha)
US OTC Competitive Dynamics
- Question: Any meaningful changes in US OTC market competition? (Nitin Agarwal - DAM Capital)
- Answer: No meaningful change in competitive intensity; war hurting consumers via fuel prices; some big players struggling which benefits the company; no new entrants or exits observed. (Mark Saldanha)
Backward Integration Status
- Question: Are backward integration plans active? (Vishal Manchanda - Systematix Group)
- Answer: Not actively pursued; some DMFs developed; exploring trading business model; 65-70% of sales manufactured in India. (Mark Saldanha)
Vision 2030 & Regulatory
- Question: What will it take to become a top global consumer healthcare company by 2030? (Mihir Damania - Fident AMC)
- Answer: Focus on creating OTC brands, expanding portfolio, and investing resources; confident in direction but significant work ahead. (Mark Saldanha)
- Question: When do you expect the next US FDA inspection at the 3 plants? (Mihir Damania - Fident AMC)
- Answer: No definite timeline; inspections can occur anytime based on filings; one plant audited less than 12 months ago. (Mark Saldanha)
Key Takeaway
Marksans Pharma delivered a record Q1 FY27 with revenue of ₹840.8 crores (+35.6% YoY), highest-ever EBITDA of ₹213 crores (25.3% margin, +919 bps YoY), and PAT of ₹159.4 crores (+173.9% YoY), while cash crossed ₹1,000 crores. Europe emerged as a strategic growth engine with UK/Europe revenue up 74.7% YoY to ₹356 crores, including ₹44 crores from Clinique BV; ABC Now GmbH (Germany) consolidates from Q2. Management maintained FY27 guidance of 15-20% revenue growth and 20-21% EBITDA margin citing geopolitical volatility, though 21-22% EBITDA was termed achievable. Strategy centers on European expansion (~₹1,000 crores in 3-5 years), US scaling toward $300 million, and doubling product portfolios across geographies; FY27 earmarked for inorganic execution. Watch points include gross margin normalization to 55-56%, war-driven cost inflation, US tariff policy, and manufacturing capacity needs.